CureVac NV (CVAC:NASDAQ), which is focused on the development of therapeutic medicines and vaccines based upon messenger ribonucleic acid (mRNA), announced today that it has concluded exploratory talks with the European Commission outlining "an Advanced Purchase Agreement for its potential mRNA-based COVID-19 vaccine."
CureVac indicated that once its mRNA-based vaccine has been proven to be safe and effective against COVID-19, it envisions that its contract with the European Commission will be structured for the firm to supply all EU member states with up to 225 million doses with an option for the purchase of 180 million additional doses.
The firm noted that its mRNA-based SARS-CoV-2 vaccine candidate is presently being evaluated in a Phase 1 clinical trial at sites in Germany and Belgium. The company advised that the study's primary objectives are to determine optimal dosage amounts and to evaluate the safety and immunological profile of the vaccine in humans. CureVac stated that it expects to receive the first results from the study in early Q4/20 and plans to use that data in order to initiate a Phase 2b/3 clinical trial also in Q4/20.
CureVac CEO Dr. Franz-Werner Haas commented, "In the current pandemic, we are very pleased to further strengthen the European Commission's endeavor to provide rapid access to a safe and effective vaccine against the COVID-19 virus across Europe and beyond. Assuming positive results from our ongoing clinical trials and approval from the regulatory authorities, we are fully committed to ensure broad access to our vaccine."
CureVac is a global clinical-stage biopharmaceutical company based in Tübingen, Germany with offices in Frankfurt and Boston. The firm concentrates its efforts on developing novel medicines that utilize messenger RNA (mRNA) as a data carrier for information to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company listed that "it applies its technologies for the development of prophylactic vaccines, cancer therapies, antibody therapies and the treatment of rare diseases."
CureVac NV started the day with a market capitalization of around $10.1 billion with approximately 178 million shares outstanding. CVAC shares opened nearly 11% higher today at $63.00 (+$6.10, +10.72%) over yesterday's $56.90 closing price. The stock has traded today between $60.70 and $66.88 per share and is currently trading at $64.71 (+$7.81, +13.73%).
[NLINSERT]Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
